APVO News & Events

Aptevo Therapeutics announced executive leadership transitions to support the Company's continued execution, drive achievement of long-term strategic objectives, and next phase of growth. Effective April 1, Marvin White, who has served as President and CEO since 2016, has chosen to retire from this position and assume the role of Executive Chair, where he will focus on cultivating strategic opportunities to help shape long-term success. Jeff Lamothe, currently COO, will assume the role of President and CEO and will join Aptevo's Board of Directors. John Niederhuber will transition from Chairman of the Board to Lead Independent Director.

Aptevo Therapeutics files to sell 7.075M shares of common stock for holders

Aptevo Therapeutics entered into a $60M equity line of credit agreement with Yorkville Advisors Global, LP, strengthening the Company's financial flexibility as it continues to advance its clinical and preclinical pipeline of multispecific anti-cancer agents that are differentiated by design. The facility provides Aptevo with access to capital, allowing the Company to raise funds incrementally, at its discretion, and under market-based conditions. Further, an ELOC offers affordable capital financing with minimal fees and no warrants. Proceeds from the ELOC will be used to support ongoing clinical development, advance preclinical programs, and fund general corporate purposes.

Aptevo Therapeutics trading halted, news pending